4. 培養方法的選擇
本文列出迄今為止最常用的三種BMDC培養方法，我們從下表中可以更清楚地看出這三種方法的異同，相信您能根據您的需要作出正確的判斷。
注：1. 該表是從文獻[8]修改和添加而來；
2. 這里的Inaba法指的是其原法[2],而不是本文中的改良法。
【BMDC 培養試劑推薦】
| 生產商 | 產品名稱 | 產品編號 | 產品規格 | 使用濃度 |
| PeproTech | 重組小鼠 GM-CSF | 315-03 | 5μg/20μg/50μg/100μg/250μg/500μg/1mg | 25-50ng/ml |
| PeproTech | 重組小鼠 IL-4 | 214-14 | 5μg/20μg/50μg/100μg/250μg/500μg/1mg | 10-40ng/ml |
| PeproTech | 重組小鼠 TNF-α | 315-01A | 5μg/20μg/50μg/100μg/250μg/500μg/1mg | 25-50ng/ml |
| PeproTech | 重組小鼠 sCD40L | 315-15 | 5μg/25μg/100μg/250μg/500μg/1mg | 1μg/ml |
【BMDC 鑒定試劑推薦】
| 生產商 | 產品名稱 | 產品編號 | 克隆號 | 熒光標記 | 產品規格 |
| PeproTech(BioGems) | 抗小鼠 CD11c熒光標記抗體 | 3212 | N418 | FITC/PE/APC/PerCP-Cy5.5 /APC-Cy7/PE-Cy7 | 25μg/100μg/500μg |
| 抗小鼠 CD40熒光標記抗體 | 2512 | HM40-3 | FITC | 50μg/100μg/500μg/1000μg | |
| 抗小鼠 CD80熒光標記抗體 | 2912 | 16-10A1 | FITC/PE/APC | 25μg/100μg/500μg | |
| 抗小鼠 CD86熒光標記抗體 | 8912 | GL-1 | FITC/PE/APC/PE-Cy7 | 25μg/100μg/500μg | |
| 抗小鼠 MHC II類分子(I-A/I-E)熒光標記抗體 | 86212 | M5/114.15.2 | FITC/PE/APC/PE-Cy7 | 25μg/100μg/200μg /500μg |
注：用于DC鑒定的表面標志物的表達在流式圖上均呈現單個峰，且多數情況下不能與陰性峰完全區分開來。為避免多色分析時補償調節不好導致結果的不準確性，建議最好用單標，最多用雙標來做DC表面標志的分析，而且必須使用同型對照，而非空白細胞對照來
排除背景染色。
【參考文獻】
[1] Steinman RM, Cohn ZA.
Identification of a novel cell type in peripheral lymphoid organs of
mice. I. Morphology, quantitation, tissue distribution. J. Exp. Med.
1973; 137 （5）： 1142–62.
[2] Inaba K, Steinman RM, et. al.
Identification of proliferating dendritic cell precursors in mouse
blood. J. Exp. Med. 1992; 175（5）：1157-67.
[3] Inaba K, Inaba M,
et. al. Generation of large numbers of dendritic cells from mouse bone
marrow cultures supplemented with granulocyte/macrophage
colony-stimulating factor. J. Exp. Med. 1992; 176（6）：1693-702.
[4] Romani N, Gruner S, et. al. Proliferating dendritic cell progenitors in human blood. J. Exp.
Med. 1994; 180（1）：83-93.
[5]
Zorina T, Mayordomo JI, et. al. Culture of dendritic cells from murine
bone marrow supplemented with GM-CSF and TNF-alpha J. Immunother. 1994;
16（3）：247.
[6] Mayordomo JI, Zorina T, et. al. Bone
marrow-derived dendritic cells pulsed with synthetic tumour peptides
elicit protective and therapeutic antitumour immunity. Nat Med.
1995;1（12）：1297-302.
[7] Labeur MS, Roters B, et. al.
Generation of tumor immunity by bone marrow-derived dendritic cells
correlates with dendritic cell maturation stage. J Immunol.
1999;162（1）：168-75.
[8] Lutz MB, Kukutsch N, et. al. An advanced
culture method for generating large quantities of highly pure
dendritic cells from mouse bone marrow. J Immunol Methods.
1999;223（1）：77-92.
[9] Son YI, Egawa S, et. al. A novel
bulk-culture method for generating mature dendritic cells from mouse
bone marrow cells. J Immunol Methods. 2002; 262（1-2）：145-57.
[10]
Inaba, K., Romani, N., et al. Generation of dendritic cells from
proliferating mouse bone marrow progenitors. In: Coico, R., Ranz, A.,
Kruisbeek,A.M. （Eds.）， Current Protocols in Immunology.Wiley, New York.
1998; Unit 3.7.